BioCryst Pharma Revenue, Profits - BCRX Annual Income Statement

Add to My Stocks
$7.32 $0.04 (0.55%) BCRX stock closing price Sep 24, 2018 (Closing)

Stock analysis based on fundamentals means looking at financial statements in addition to the BioCryst Pharma stock price. The income statement is a summary of the revenue or sales, expenses and profitability - shown as Net Income, or lack of it. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from 26.35M to 25.18M and how operating and non operating activities have impacted the BCRX stock. One also needs to look at BioCryst Pharma assets, operating expenses and BioCryst Pharma free cash flow. The BioCryst Pharma profit and loss statement shows revenue of $25.18M for 2017. Revenue has decreased by -4.44% YOY for BCRX stock.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
BioCryst Pharma Revenues or Net Sales
25.18M26.35M48.25M13.6M17.33M26.29M19.64M62.38M74.58M56.56M
Cost Of Goods Sold (COGS)1.14M2.29M1.36M-----4.54M-
BioCryst Pharma Gross Profit
24.04M24.05M46.88M13.6M17.33M26.29M19.64M62.29M70.04M56.56M
Research & Development Expense66.96M61M72.75M51.79M42.73M51.46M56.89M82.47M72.3M73.32M
Selling General & Admin Expense14.49M11.65M13.57M7.58M5.31M8.71M12.33M14.17M11.48M10.39M
Income Before Depreciation Depletion Amortization-57.41M-48.6M-39.44M-45.77M-30.71M-33.88M-53.36M-34.35M-13.73M-27.16M
Depreciation Depletion Amortization----------
Non Operating Income--0.05M1.62M5.58M5.38M-0.52M-3.58M--2.43M
Interest Expense8.56M6.48M5.2M4.99M4.77M4.66M3.77M---
BioCryst Pharma Pretax Income
-65.78M-55.14M-43.01M-45.18M-30.1M-39.08M-56.94M-33.85M-13.45M-24.73M
Provision for Income Taxes----------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-65.78M-55.14M-43.01M-45.18M-30.1M-39.08M-56.94M-33.85M-13.45M-24.73M
Extraordinary Items & Discontinued Operations----------
BioCryst Pharma Profit/ Loss (Net Income)
-65.78M-55.14M-43.01M-45.18M-30.1M-39.08M-56.94M-33.85M-13.45M-24.73M
Average Shares used to compute Diluted EPS84.45M73.7M72.9M66.77M55.22M49.47M45.14M44.56M38.93M38.06M
Average Shares used to compute Basic EPS84.45M73.7M72.9M66.77M55.22M49.47M45.14M44.56M38.93M38.06M
Income Before Nonrecurring Items-65.78M-55.14M-43.02M-45.19M-30.11M-37.94M-56.95M-32.73M-13.45M-24.73M
Income from Nonrecurring Items------1.14M----
BioCryst Pharma Earnings Per Share Basic Net
-0.78-0.75-0.59-0.68-0.55-0.79-1.26-0.73-0.35-0.65
BioCryst Pharma Earnings Per Share Diluted Net
-0.78-0.75-0.59-0.68-0.55-0.79-1.26-0.73-0.35-0.65
EPS Diluted Before Nonrecurring Items-0.78-0.75-0.59-0.68-0.55-0.77-1.26-0.73-0.35-0.65
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Click here to view our BioCryst Pharma financial analysis

BioCryst Pharma stock analysis involves checking at least a few of the important things like:

  • Revenue: The money received by selling of goods or services comes under this line item. A YoY growth - See: BioCryst Pharma revenue chart implies that the company is growing. It has not been the case with BioCryst Pharma. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-65.78M for BCRX stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called the profit and loss statement. Apart from the BCRX income statement, one can check the BioCryst Pharma historical stock prices to check how the price has moved with time.

BioCryst Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
24.83
Dividend Yield
0%